Noninvasive Prenatal Testing Market Size, Share, and Trend Analysis Report by Gestation Period, by Pregnancy Risk, by Method, by Technology, by Product, by Application, by End-Use, by Region & Region segment forecast, 2022

ReportLinker

Noninvasive Prenatal Testing Market Size, Share, and Trend Analysis Report by Gestation Period, by Pregnancy Risk, by Method, by Technology, by Product, by Application, by End-Use, by Region & Region segment forecast, 2022-2030

New York, Sept. 13, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Non Invasive Prenatal Testing Market Size, Share & Trends Analysis Report By Gestation Period, By Pregnancy Risk, By Method, By Technology, By Product , by Application, by End Use, by Region and Segment Forecast, 2022 – 2030” – https://www.reportlinker.com/p06318486/?utm_source=GNW

Non-Invasive Prenatal Testing Market Growth and Trends

The global non-invasive prenatal testing market size is expected to reach USD 7.71 billion by 2030, growing at a CAGR of 9.61% from 2022 to 2030. Rising incidence of chromosomal abnormalities is expected to accelerate market growth. Of all countries, there is a substantial opportunity in China for non-invasive prenatal screening, with nearly 14.65 million births annually and a growing number of high-risk pregnancies.

Also, India has a heavy burden of genetic diseases. Various studies have suggested that chromosomal abnormalities are found with a frequency of 1 in 166 newborns in the country, while trisomy 21 (Down syndrome) has a high incidence rate of 1 in 800 births, resulting in the birth than 32,000 newborn babies with Down syndrome each year.

Families can benefit from accurate and early screening using the NIPT to learn about their baby’s genetic problem. Thus, this high incidence rate is expected to drive demand for prenatal testing.

With COVID-19 lockdowns, NIPT has gained attention because it offers high-accuracy screening with minimal risk of infection compared to invasive procedures such as chorionic villus sampling and amniocentesis, which can both require hospitalization and put patients and healthcare professionals at risk of contracting the COVID-19 infection. Additionally, there was an increase in demand for NIPT prescription; however, it was limited to a smaller number of eligible people due to lack of infrastructure and the adoption of telemedicine facilities in most countries.

The reimbursement scenario for non-invasive prenatal screening is highly variable. However, government support and favorable insurance policies are driving the market growth.

For example, in the Netherlands, prenatal screening fees are fully reimbursed in the second trimester, leading to increased uptake of these tests. Rising government initiatives to encourage the bio and pharmaceutical industry in emerging economies such as India and China are expected to drive the demand for non-invasive prenatal screening solutions and services.

The major players in the market are focusing on the development of new products to strengthen their product portfolios and offer innovative products to their customers. In March 2020, Agilent Technologies launched three new DNA chips to support prenatal and postnatal research in cytogenetics laboratories.

Probes on cyto microarrays provide high-resolution detection of copy number variation and loss of copy-neutral heterozygosity related to neuropsychiatric disorders, developmental delay, intellectual disability, and birth defects in human specimens. Constitutional DNA.

Noninvasive Prenatal Testing Market Report Highlights
• By gestation period, 13-24 weeks led the market in 2021 due to the peak number of non-invasive prenatal procedures performed in the second trimester of pregnancy
• The low risk pregnancy risk segment is expected to grow significantly over the forecast period. Government support such as budget allocation for medium risk pregnancies has contributed to segment growth
• Based on product, the cell-free DNA in maternal plasma testing segment accounted for the largest revenue share in 2021. Cell-free DNA is increasingly used to predict the risk of genetic disorders in healthcare prenatal via various genetic analyzes
• Asia-Pacific is expected to show the highest CAGR during the forecast period. Rising maternal age and improved healthcare infrastructure are expected to enhance market growth
• North America led the market in 2021 due to high R&D investments, presence of advanced healthcare institutions and development of whole genome sequencing
Read the full report: https://www.reportlinker.com/p06318486/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Comments are closed.